Relying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
Relying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
We are developing a series of molecularly targeted products for the diagnosis and treatment of cancer, that will redefine the next generation of radiopharmaceuticals based on product and technology innovations.
View moreTelix Completes Acquisition of ARTMS, and its Advanced Isotope Production Platform
GT Medical Technologies, Inc. Completes Strategic Acquisition of Radioactive Seed Assets from Perspective Therapeutics, Inc.
The New Radiopharma Competition Requires Unprecedented Medical Logistics
Imaging with [99m]Tc-Maraciclatide Correlates with Identification of Early-Stage Endometriosis by Laparoscopic Surgery
PET/MRI findings ‘encouraging’ for people with late-life depression
First patient dosed with TLX250-CDx in Italy for ccRCC